SPPI News and Press, Spectrum Pharmaceuticals Inc. From 11/07/19

Spectrum Pharmaceuticals (NASDAQ: SPPI ): Q3 Non-GAAP EPS of -$0.22; GAAP EPS of -$0.24 beats by $0.17 . Cash & equivalents of $252M. Press Release More news on: Spectrum Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,

Topline data from Cohort 1 of ZENITH20 trial evaluating poziotinib for NSCLC expected in December Basket trial initiated to study poziotinib in patients with EGFR or HER2 mutation-positive malignant solid tumors in an investigator-led study at The University of Texas MD Anderson Cancer...

Spectrum Pharmaceuticals (NASDAQ: SPPI ) is scheduled to announce Q3 earnings results on Thursday, November 7th, after market close. The consensus EPS Estimate is -$0.41 (-141.2% Y/Y) Over the last 2 years, sppi has beaten EPS estimates 63% of the time and has beaten revenue estimate...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today it will host a conference call with management to discuss the third quarter 2019 financial results, provide an update on the company's business, and discuss...

ROLONTIS BLA filing is based on two large pivotal randomized controlled studies that met all primary and secondary endpoints. ROLONTIS is a novel, long-acting granulocyte colony-stimulating factor (G-CSF) seeking an indication for the treatment of neutropenia in patients receiving myel...

Spectrum Pharmaceuticals (NASDAQ: SPPI ) announces a publication entitled, “Pan-Cancer Landscape and Functional Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.” More news on: Spectrum Pharmaceuticals, Inc., ...

Publication highlights pre-clinical and clinical activity of poziotinib in lung cancer patients with HER2 mutations and potential future applications using monotherapy and combinations in many different mutated cancers Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutica...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage programs will be given at the 2019 Cantor Global Healthcare Conference being hel...

Gainers:  NSPR   +6.4% . YUMA   +5.5% . SPPI   +4.3% . TLRD   +2.4%.  SRCI   +2.2% . More news on: InspireMD, Inc., Yuma Energy, Inc., Spectrum Pharmaceuticals, Inc., Stocks on the move, Read more ...

Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, is developing poziotinib in non-small cell lung cancer (NSCLC) EGFR exon 20 mutations and beyond. New clinical data from the poziotinib Phase 2 investigator-initiate...